NOACs show benefit in secondary prevention: study

Novel oral anticoagulants (NOACs) could be added to the recommended list of secondary prevention drugs for those who have had a coronary event, cardiologists say.

Adding rivaroxaban to the usual antiplatelet prevention strategy of aspirin improved cardiovascular outcomes significantly, albeit at the cost of increased risk for bleeding, a major study has shown.

The prospective randomised trial of 27,395 patients with stable cardiovascular disease showed that a combination of low-dose rivaroxaban (2.5mg twice daily) plus aspirin (100mg) reduced the relative risk of